{"id":569,"date":"2025-02-10T13:37:00","date_gmt":"2025-02-10T19:37:00","guid":{"rendered":"https:\/\/www.rqmplus.com\/?p=569"},"modified":"2025-06-03T11:14:10","modified_gmt":"2025-06-03T16:14:10","slug":"tricuspid-brinkmanship-are-we-overhyping-the-right-sided-revolution","status":"publish","type":"post","link":"https:\/\/www.rqmplus.com\/blog\/tricuspid-brinkmanship-are-we-overhyping-the-right-sided-revolution\/","title":{"rendered":"Tricuspid Brinkmanship: Are We Overhyping the Right-Sided Revolution?"},"content":{"rendered":"\n

The Hype Train Has Left the Station\u2026 But Where\u2019s the Track?<\/h2>\n\n\n\n

The tricuspid valve is having a moment; it\u2019s no longer cardiology’s wallflower, it’s the toast of the town, sparking dreams in cath labs and boardrooms alike. Once an overlooked oddity, it now stars in high-octane studies like TRILUMINATE and TRISCEND II, igniting debates on whether tricuspid repairs (and replacements) are the next big wave or just a tempest in a teapot. But let’s not pop the champagne just yet. Are we gearing up for a breakthrough, or setting the stage for a high-stakes fizzle, reminiscent of earlier transcatheter misadventures? The unique challenges of right-sided heart anatomy (and hemodynamics) demand more than a cursory glance. So, before we toast to the “right-sided revolution,” we need to ask: Is this genuine progress or just a game of medical Jenga?<\/p>\n\n\n\n

Join me as we peel back the layers of hype, examining these trials from all angles: industry, patients, regulators, and payers. Let’s sift the real from the hype and see if these interventions will deliver on their grand promises, or if they’re destined to be engulfed by their own hubris.<\/p>\n\n\n\n

Advancing tricuspid innovation is a bit like sending a rover to Mars; exciting, expensive, and everyone\u2019s watching to see if it\u2019ll crash.<\/em><\/h4>\n\n\n\n

Heart Valve: When It Flunks the Tight-Seal Test<\/h2>\n\n\n\n

Tricuspid Regurgitation (TR), or as I like to call it, “the leaky valve fiasco,” is when your heart’s tricuspid valve is more about freedom than control, letting blood flow backward when it should be moving forward. Picture this: In Functional TR or the “Heart-strain leak,” the heart\u2019s chambers are like overpacked suitcases, stretched from the inside and struggling to zip up tightly, heart failure being the usual culprit. On the flip side, there’s Degenerative TR or “Wear-and-tear leak,” where the valve is just tired from years of service, weathered down by age, or perhaps an infection, and not sealing like it used to. Figuring out whether your valve is overwhelmed by pressure or just a tired old gatekeeper helps zero in on how to patch things up, or when to call for backup.<\/p>\n\n\n\n

Industry Ambitions vs. Clinical Realities: Striking a Perilous Balance<\/h2>\n\n\n\n

Surge of Enthusiasm
The tricuspid market is the new El Dorado for device manufacturers, offering vast prospects for those aiming to fix the infamous “leaky valve fiasco.” Much like the gold rush days of early TAVR, there\u2019s a fortune to be made for devices designed for patients previously written off.<\/p>\n\n\n\n

Cautionary Tales
Yet, history serves up a reality check as icy as a clinical cold room: what sparkles in trial settings often dulls under the intense scrutiny of real-world applications. The diversity of patient populations and the whimsical nature of TR grading can turn controlled environments into wild cards. Today’s petite trials, with their cherry-picking finesse, resemble more of a magician\u2019s parlor trick than a steadfast scientific endeavor. We risk swapping rigorous validation for a credibility clearance sale.<\/p>\n\n\n\n

Bottom Line:\u00a0<\/strong>Manufacturers are betting big, but the true jackpot lies in backing bold claims with solid, incontrovertible evidence<\/a>. Without it, they gamble not just with fortunes but with lives, and in the high stakes game of heart health, the final call will always demand hard proof over hype.<\/p>\n\n\n\n

Tricuspid devices are like teenagers full of potential and bluster, but can they really clean up their act when put to the test?<\/em><\/h4>\n\n\n\n

Parsing the Triumphs and Tensions<\/h2>\n\n\n\n

TRILUMINATE: A Masterclass in Smoke and Mirrors?<\/p>\n\n\n\n

The star of today\u2019s show is TRILUMINATE, featuring 600 volunteers in a spectacle comparing transcatheter edge-to-edge repair (with the TriClip) to standard medical therapy. The headliner (primary endpoint)? A composite endpoint of mortality, surgeries, hospitalizations, and everyone\u2019s favorite subjective measurement i.e., quality of life improvements via KCCQ. Surprise! The only \u201cwin\u201d came from subjective patient questionnaires. Death? Surgery? Hospitalizations? Crickets. The results glow brightly, but only if you’re measuring the applause meter, not the survival rate. <\/p>\n\n\n\n

We didn\u2019t save lives, but hey, patients felt better! Maybe it was the clip\u2026 or maybe it was the placebo effect. Who cares? \u2026Win ratio!<\/em><\/h4>\n\n\n\n

If feeling better is enough, maybe we should prescribe spa days instead of clips.<\/em><\/h4>\n\n\n\n

The TRILUMINATE imaging sub study adds precious little since firstly, all blinding is out of the window as the clip is clearly visible and secondly, it lacks hard outcome benefits.  <\/p>\n\n\n\n

What\u2019s missing? A placebo act. That’s right, no dummy run. This study compared transcatheter edge-to-edge repair with the TriClip system to\u2026 checks notes\u2026 pills. Yes, pills. Surely, nothing screams \u201cscientific rigor\u201d like pitting a $30K device against prescription pills. \u00a0Evaluating an invasive procedure<\/a> without a placebo control is like judging a magic show based solely on the magician\u2019s charisma rather than his tricks. The outcome dazzles the naive but leaves the skeptics wanting. \u00a0<\/p>\n\n\n\n

A Flicker of Reality: The PASUTA Registry<\/p>\n\n\n\n

Not all is lost in the realm of observational studies. The PASUTA registry offers a sliver of real-world data with 1,000 patients showing some benefits from the newer gadget on the block (Pascal device).  The registry included consecutive patients, which is a strength, as voluntary registries often exclude unfavorable cases. For results, clinical outcomes remain meaningless without a control arm and complications were underreported (\u201cno major complications\u201d is rather vague). Once again, without a control group, it\u2019s like relying on audience cheers to gauge a film\u2019s Oscar worthiness. It’s nice to hear, but where’s the critical acclaim?<\/p>\n\n\n\n

Let\u2019s not forget that registry studies can describe trends but cannot prove effectiveness. <\/em>
Imagine the insights if these 1,000 patients had been randomized with a sham control arm!<\/em><\/h4>\n\n\n\n

TRISCEND II: When \u201cInnovation\u201d Means Trading Bleeding for Surveys<\/p>\n\n\n\n

Then there\u2019s TRISCEND II, which feels like a rerun of a show you didn\u2019t want to watch the first time. If TRILUMINATE was a magic trick, TRISCEND II is the encore where the rabbit gets eaten by the hat. It follows the same script; big promises based on subjective quality-of-life scores, with no significant impacts on the endpoints that actually matter: death and hospital stays. But wait, there\u2019s more: a 3X increase in bleeding and a need for 9X more pacemakers (because who doesn\u2019t love a side of lead extraction?). Remember these involved specialized coronary sinus leads or leadless pacemakers. Talk of residual risks\u2026and costs. If complications were dollars, we\u2019d all be millionaires.<\/p>\n\n\n\n

Moving on, this rerun focuses solely on quality-of-life data; unsurprising, as it\u2019s the only positive aspect. My critique remains unchanged: Without placebo controls, these trials are scientifically inadequate.<\/p>\n\n\n\n

 If complications were confetti, this trial would be a parade.<\/em><\/h4>\n\n\n\n

Tricuspid “Fixer-Upper”: When the Cure is a Cardiac Backstab<\/p>\n\n\n\n

Here\u2019s the cold truth:<\/strong> Mending a leaky tricuspid valve is like silencing a smoke alarm while the house burns down. Sure, transcatheter gadgets stop the drip but they might also drop a hemodynamic anvil on the right ventricle. That cozy, low-pressure right ventricle (RV) gets sucker-punched by afterload whiplash and it\u2019s not a mere hiccup.  It is a cardiac horror show. We\u2019re not just fixing valves; we\u2019re playing Jenga with anatomy. Yank one wobbly block (regurgitation), and the tower (RV function) collapses. The result? A \u201ccure\u201d that\u2019s less miracle and more \u201cOops, we turned your heart into a ticking time bomb.\u201d<\/p>\n\n\n\n

Before slapping \u201crevolutionary\u201d on every catheter-delivered widget, remember: The heart isn\u2019t LEGO. Nuance isn\u2019t optional, it\u2019s the line between hero and \u201cRV Failure: The Director\u2019s Cut.\u201d<\/em><\/h4>\n\n\n\n

Science: Nothing But Roadkill on The Highway to Innovation<\/p>\n\n\n\n

Once a device hits the market and CMS starts writing checks, clinical equipoise doesn\u2019t just vanish, it\u2019s vaporized by the thermonuclear blast of corporate momentum. The moment reimbursement codes drop, rigorous trials go from \u201cethically essential\u201d to \u201ccommercially irrelevant.\u201d Why? \u2026because in today\u2019s healthcare ecosystem, approval isn\u2019t a scientific milestone, it\u2019s a fiscal finish line.<\/p>\n\n\n\n

Imagine this: You\u2019re a researcher trying to run a sham-controlled trial for a device already plastered on billboards and touted by \u201ckey opinion leaders\u201d wearing sponsored lab coats. Good luck recruiting patients who\u2019d willingly risk getting the placebo when Dr. Instagram already told them the device is \u201crevolutionary.\u201d The scientific method? More like the scientific meth-head desperate, erratic, and chasing the next quick high.<\/p>\n\n\n\n

Take TRILUMINATE and TRISCEND II, poster children for this farce. These trials didn\u2019t just bend the rules; they snapped them over a knee and tossed the pieces into a quality-of-life survey bonfire. Once CMS reimburses these devices, future trials won\u2019t ask, \u201cDoes this work?\u201d They\u2019ll ask, \u201cHow fast can we upsell?\u201d<\/p>\n\n\n\n

The tragedy isn\u2019t just lost data, it\u2019s medicine\u2019s Faustian bargain: trading long-term knowledge for short-term revenue. Maybe we\u2019re practicing faith-based billing, where the dogma is written by whoever owns the patent.<\/p>\n\n\n\n

Sometimes the road to hell isn\u2019t paved with good intentions, it\u2019s reimbursed by CMS.<\/em><\/h4>\n\n\n\n

Patients on the Precipice: Hope, Hype, and the Real World<\/h2>\n\n\n\n

A New Lifeline
For those grappling with severe TR, often aged, frail, and saddled with other health woes, these devices herald a new dawn. Dodging the severe risks of open surgery is no trivial feat, and early whispers of enhanced life quality are indeed persuasive.<\/p>\n\n\n\n

Reality Check
The patient in the clinic seldom mirrors the ‘poster child’ of clinical trials. Advanced RV dysfunction and complex conditions frequently throw cold water on the grand promises of transcatheter tricuspid valve interventions. Despite the orchestrated perfection of trial settings, the real world is messier, its patients less forgiving. Manufacturers, driven by tales of unmet needs, push for wide indications at the regulatory gate, only to see early successes dwindle when faced with the gritty reality of clinical practice. This mismatch sets the stage for a drama where initial victories fade, payers wrestle with ballooning costs, and ultimately, the entire healthcare system is left holding the bag. The critical need for better trial design, sub-group analysis and comprehensive follow-up has never been clearer, to ensure that the fleeting brilliance of clinical trial success isn\u2019t overshadowed by the long-term challenges that follow.<\/p>\n\n\n\n

Question to Ponder:<\/strong> Will real-world data reveal that those with significantly dilated right ventricles experience markedly different outcomes from the general trial population?<\/p>\n\n\n\n

For patients, these new tricuspid devices promise a revolution; let\u2019s hope it\u2019s not merely a flash flood leaving no escape.<\/em><\/h4>\n\n\n\n

Raising the Stakes: The Regulator\u2019s Uncompromising Gaze<\/h2>\n\n\n\n

As a former regulator in the EU battlefields, I\u2019ve watched as gatekeepers elevate standards for clinical evidence, particularly when it comes to novel transcatheter cardiovascular devices.<\/p>\n\n\n\n